
Product Data Sheet

Product Name: Labetuzumab govitecan

Cat. No.: GC74567

Chemical Properties

Cas. No. 1469876-18-3

Formula M.Wt 154000 (average)

Solubility Storage -80°C, protect from light

General tips For obtaining a higher solubility , please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.

Structure

Background

Labetuzumab govitecan (IMMU 130) is an Anti-CEACAM5/SN-38 antibody-drug conjugate (ADC). Labetuzumab govitecan consists of the antibody Labetuzumab, SN-38, and a pH-sensitive Linker. Labetuzumab govitecan can be used for research of cancers, such as colorectal cancer.

Labetuzumab govitecan (total of 1.0 mg, i.p.) prolongs median survival of GW-39 lung metastatic mouse model[2]. Labetuzumab govitecan (25 mg/kg, i.p., twice weekly for 4 weeks) prolongs median survival of sc LS174T Xenograft in nude mice[2].

References:

[1]. Dotan E, et al. Phase I/II Trial of Labetuzumab Govitecan (Anti-CEACAM5/SN-38 Antibody-Drug Conjugate) in Patients With Refractory or Relapsing Metastatic Colorectal Cancer. *J Clin Oncol*. 2017 Oct 10;35(29):3338-3346.

[2]. Govindan SV, et al. Improving the therapeutic index in cancer therapy by using antibody-drug conjugates designed with a moderately cytotoxic drug. *Mol Pharm*. 2015 Jun 1;12(6):1836-47.

[3]. Criscitiello C, et al. Antibody-drug conjugates in solid tumors: a look into novel targets. *J Hematol Oncol*. 2021 Jan 28;14(1):20.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA